Kymera Therapeutics filed patents describing STAT6 inhibitors intended for a broad range of indications including cancer, inflammatory disorders and neurodegeneration. The patent disclosures outline chemotypes and biological data supporting STAT6 modulation as a therapeutic strategy to alter transcriptional programs linked to type‑2 immunity and tumor biology. STAT6 inhibition represents a transcription-factor targeting approach that may reprogram immune microenvironments and tumor biology. For drug discovery teams: STATs are challenging targets—patent coverage signals Kymera’s intent to build a portfolio potentially complementary to its targeted protein degradation expertise.